NasdaqCM - Nasdaq Real Time Price USD

Cue Biopharma, Inc. (CUE)

0.6020
-0.0337
(-5.30%)
At close: June 13 at 4:00:02 PM EDT
0.6100
+0.01
+(1.33%)
After hours: June 13 at 6:26:52 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
7,991
9,287
5,490
1,245
14,941.3700
Operating Expense
49,215
50,880
57,482
54,747
58,653.4430
Operating Income
-41,224
-41,593
-51,992
-53,502
-43,712.0730
Net Non Operating Interest Income Expense
547
826
1,416
215
45.8980
Other Income Expense
64.0780
93
-157
277
--
Pretax Income
-40,584
-40,674
-50,733
-53,010
-43,666.1750
Tax Provision
--
--
--
0
495
Net Income Common Stockholders
-40,584
-40,674
-50,733
-53,010
-44,161.1750
Diluted NI Available to Com Stockholders
-40,584
-40,674
-50,733
-53,010
-44,161.1750
Basic EPS
-0.64
-0.72
-1.11
-1.49
-1.41
Diluted EPS
-0.64
-0.72
-1.11
-1.49
-1.41
Basic Average Shares
62,525.3450
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Diluted Average Shares
62,525.3450
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Total Operating Income as Reported
-41,131
-41,500
-52,149
-53,225
-43,712.0730
Rent Expense Supplemental
--
--
716
899
--
Total Expenses
49,215
50,880
57,482
54,747
58,653.4430
Net Income from Continuing & Discontinued Operation
-40,584
-40,674
-50,733
-53,010
-44,161.1750
Normalized Income
-40,677
-40,767
-50,576
-53,287
-44,161.1750
Interest Income
1,230
1,622
2,661
928
45.8980
Interest Expense
683
796
1,245
713
0
Net Interest Income
547
826
1,416
215
45.8980
EBIT
-39,901
-39,878
-49,488
-52,297
-43,666.1750
EBITDA
-37,518
-37,528
-46,052
-50,491
-43,666.1750
Reconciled Depreciation
2,383
2,350
3,436
1,806
-1,777.9850
Net Income from Continuing Operation Net Minority Interest
-40,584
-40,674
-50,733
-53,010
-44,161.1750
Total Unusual Items Excluding Goodwill
93
93
-157
277
0
Total Unusual Items
93
93
-157
277
0
Normalized EBITDA
-37,611
-37,621
-45,895
-50,768
-43,666.1750
Tax Rate for Calcs
0
0
0
0
0.0003
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/2/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EXOZ eXoZymes, Inc.
12.81
-8.21%
 
SNSE Sensei Biotherapeutics, Inc.
0.3000
-10.58%
 
RNTX Rein Therapeutics Inc.
1.8800
-2.59%
 
ACTU Actuate Therapeutics, Inc. Common stock
8.65
+0.46%
 
HOOK HOOKIPA Pharma Inc.
1.4200
0.00%
 
IPHA Innate Pharma S.A.
1.8950
-4.05%
 
ELVN Enliven Therapeutics, Inc.
21.91
+11.44%
 
CASI CASI Pharmaceuticals, Inc.
1.8400
+1.71%
 
BVNRY Bavarian Nordic A/S
9.41
-0.82%
 
ATXS Astria Therapeutics, Inc.
5.72
+2.14%